ESPR · Esperion Therapeutics, Inc.
No Price Data
No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Q4 retail prescription equivalents sequential Q/Q growth | 11.3% | Q4 2025 | — |
| Q4 retail prescription equivalents Y/Y growth | 34% | Q4 2025 | — |
| Commercial lives covered | 90% | Full-Year 2025 | — |
| Healthcare providers prescribing NEXLETOL and NEXLIZET | 44,991 | Full-Year 2025 | — |
| Medicare beneficiaries covered | 90% | Full-Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ESPR
this stock
Esperion Therapeutics, Inc.
|
$818.63M | — | +21.3% | — | 6.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding